RESUMO
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder characterized by inflammatory assaults on the central nervous system (CNS), particularly on the optic nerves and spinal cord. In recent years, a wider range of clinical manifestations of this complex disease have been observed, emphasizing the importance of gaining a more profound understanding beyond optic neuritis (ON) and transverse myelitis (TM). CURRENT KNOWLEDGE: This study explores the many clinical symptoms of NMOSD, including common and uncommon presentations. Distinctive aspects of ON, TM, and diencephalic/brainstem syndromes are examined, highlighting their unique characteristics in contrast to conditions such as multiple sclerosis. We also discuss extra-CNS involvement, such as unusual signs, including muscle involvement, retinal injury, auditory impairment, and rhinological symptoms. AIMS AND OBJECTIVES: Our study intends to highlight the wide range and complexity of NMOSD presentations, emphasizing the significance of identifying unusual symptoms for precise diagnosis and prompt management. The specific processes that contribute to the varied clinical presentation of NMOSD are not well understood despite existing information. This emphasizes the necessity for more study to clarify the mechanisms that cause different symptoms and discover new treatment targets for this complex autoimmune disorder. CONCLUSION: It is essential to acknowledge the complex and varied clinical manifestations of NMOSD to enhance diagnosis, treatment, and patient results. By enhancing our comprehension of the fundamental processes and investigating innovative therapeutic approaches, we may aim to enhance the quality of life for persons impacted by this illness.
Assuntos
Neuromielite Óptica , Neuromielite Óptica/diagnóstico , Neuromielite Óptica/fisiopatologia , HumanosRESUMO
There is debate on the role of glial fibrillary acidic protein (GFAP) as a reliable biomarker in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), and its potential to reflect disease progression. This review aimed to investigate the role of GFAP in MS and NMOSD. A systematic search of electronic databases, including PubMed, Embase, Scopus, and Web of Sciences, was conducted up to 20 December 2023 to identify studies that measured GFAP levels in people with MS (PwMS) and people with NMOSD (PwNMOSD). R software version 4.3.3. with the random-effect model was used to pool the effect size with its 95% confidence interval (CI). Of 4109 studies, 49 studies met our inclusion criteria encompassing 3491 PwMS, 849 PwNMOSD, and 1046 healthy controls (HCs). The analyses indicated that the cerebrospinal fluid level of GFAP (cGFAP) and serum level of GFAP (sGFAP) were significantly higher in PwMS than HCs (SMD = 0.7, 95% CI: 0.54 to 0.86, p < 0.001, I2 = 29%, and SMD = 0.54, 95% CI: 0.1 to 0.99, p = 0.02, I2 = 90%, respectively). The sGFAP was significantly higher in PwNMOSD than in HCs (SMD = 0.9, 95% CI: 0.73 to 1.07, p < 0.001, I2 = 10%). Among PwMS, the Expanded Disability Status Scale (EDSS) exhibited significant correlations with cGFAP (r = 0.43, 95% CI: 0.26 to 0.59, p < 0.001, I2 = 91%) and sGFAP (r = 0.36, 95% CI: 0.23 to 0.49, p < 0.001, I2 = 78%). Regarding that GFAP is increased in MS and NMOSD and has correlations with disease features, it can be a potential biomarker in MS and NMOSD and indicate the disease progression and disability in these disorders.
Assuntos
Biomarcadores , Proteína Glial Fibrilar Ácida , Esclerose Múltipla , Neuromielite Óptica , Humanos , Neuromielite Óptica/sangue , Neuromielite Óptica/fisiopatologia , Neuromielite Óptica/diagnóstico , Proteína Glial Fibrilar Ácida/sangue , Proteína Glial Fibrilar Ácida/análise , Proteína Glial Fibrilar Ácida/líquido cefalorraquidiano , Esclerose Múltipla/sangue , Esclerose Múltipla/fisiopatologia , Biomarcadores/sangue , Biomarcadores/análise , Progressão da DoençaRESUMO
Cognitive impairment (CI) is prevalent in central nervous system demyelinating diseases, such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). We developed a novel tablet-based modified digital Symbol Digit Modalities Test (MD-SDMT) with adjustable protocols that feature alternating symbol-digit combinations in each trial, lasting one or two minutes. We assessed 144 patients (99 with MS and 45 with NMOSD) using both MD-SDMT protocols and the traditional paper-based SDMT. We also gathered participants' feedback through a questionnaire regarding their preferences and perceived reliability. The results showed strong correlations between MD-SDMT and paper-based SDMT scores (Pearsons correlation: 0.88 for 2 min; 0.85 for 1 min, both p < 0.001). Among the 120 respondents, the majority preferred the digitalized SDMT (55% for the 2 min, 39% for the 1 min) over the paper-based version (6%), with the 2 min MD-SDMT reported as the most reliable test. Notably, patients with NMOSD and older individuals exhibited a preference for the paper-based test, as compared to those with MS and younger patients. In summary, even with short test durations, the digitalized SDMT effectively evaluates cognitive function in MS and NMOSD patients, and is generally preferred over the paper-based method, although preferences may vary with patient characteristics.
Assuntos
Esclerose Múltipla , Neuromielite Óptica , Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Esclerose Múltipla/psicologia , Esclerose Múltipla/fisiopatologia , Neuromielite Óptica/fisiopatologia , Testes Neuropsicológicos , Disfunção Cognitiva/diagnóstico , Reprodutibilidade dos Testes , Idoso , Doenças Desmielinizantes , Inquéritos e Questionários , Adulto Jovem , Computadores de MãoRESUMO
OVERVIEW: Dysphagia has been previously discussed as a potential life-threatening condition secondary to chronic neurological diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). However, its impact on the quality of life (QoL) of patients with NMOSD has never been studied before. This study aims to determine the frequency of dysphagia and its impact on QoL in NMOSD patients in comparison with MS people and healthy individuals. METHODS: Seventy-five MS and sixty-five NMOSD patients with an expanded disability status scale (EDSS) score ≥ 3.5 in addition to 106 healthy controls were enrolled in this cross-sectional study. All the participants completed the self-report dysphagia in MS (DYMUS) and 36-item short-form health survey (SF-36) questionnaires. In case of positive answers to at least one of the questions in DYMUS, they were asked to fill out the dysphagia handicap index (DHI) questionnaire. RESULTS: The frequency of dysphagia in NMOSD, MS, and control groups was 61.54 %, 72.97 %, and 27 %, respectively. Patients with swallowing problems had reduced scores across different swallowing-related QoL domains compared to non-dysphagic patients (p < 0.05). NMOSD (1, IQR [0-3.5]) and MS patients (2, IQR [0-4]) had a significantly higher median total DYMUS score than control (0, IQR [0-1]) (p < 0.01). However, there was no discernible difference between the two patient groups. NMOSD had the highest mean total DHI score (21.22 ± 21), followed by MS (15.25 ± 18.94) and control (7.08 ± 5.12). A significant correlation was seen in the NMOSD group between the DHI total score and the SF-36 total score (r = 0.62, p < 0.05). The DHI and SF-36 subscales showed a strong association as well. The overall SF-36 scores in both the control and MS groups was not significantly correlated with DHI. The generalized linear model analysis showed that the NMOSD group's age (p-value = 0.005), EDSS (p-value < 0.001), and total DYMUS score (p-value = 0.018) significantly affected overall health status. CONCLUSION: The presence of dysphagia significantly impacts the QoL in NMOSD patients, particularly in aspects related to swallowing. These findings underscore the critical need for diligent dysphagia screening and emphasize the importance of educating both caregivers and NMOSD patients about managing this challenging symptom.
Assuntos
Transtornos de Deglutição , Esclerose Múltipla , Neuromielite Óptica , Qualidade de Vida , Índice de Gravidade de Doença , Humanos , Neuromielite Óptica/complicações , Neuromielite Óptica/fisiopatologia , Transtornos de Deglutição/etiologia , Transtornos de Deglutição/fisiopatologia , Feminino , Masculino , Esclerose Múltipla/complicações , Adulto , Estudos Transversais , Pessoa de Meia-Idade , Avaliação da DeficiênciaRESUMO
Cognitive impairment (CI) has been reported in 29-70% of patients with neuromyelitis optica spectrum disorder (NMOSD). Abnormal white matter (WM) functional networks that correlate with cognitive functions have not been studied well in patients with NMOSD. The aim of the current study was to investigate functional connectivity (FC), spontaneous activity, and functional covariance connectivity (FCC) abnormalities of WM functional networks in patients with NMOSD and their correlation with cognitive performance. Twenty-four patients with NMOSD and 24 healthy controls (HCs) were included in the study. Participants underwent brain resting-state functional magnetic resonance imaging (fMRI) and the Montreal Cognitive Assessment (MoCA). Eight WM networks and nine gray matter (GM) networks were created. In patients, WM networks, including WM1-4, WM1-8, WM2-6, WM2-7, WM2-8, WM4-8, WM5-8 showed reduced FC (P < 0.05). All WM networks except WM1 showed decreased spontaneous activity (P < 0.05). The major GM networks demonstrated increased/decreased FC (P < 0.05), whereas GM7-WM7, GM8-WM4, GM8-WM6 and GM8-WM8 displayed decreased FC (P < 0.05). The MoCA results showed that two-thirds (16/24) of the patients had CI. FC and FCC in WM networks were correlated negatively with the MoCA scores (P < 0.05). WM functional networks are multi-layered. Abnormal FC of WM functional networks and GM functional networks may be responsible for CI.
Assuntos
Substância Cinzenta , Imageamento por Ressonância Magnética , Rede Nervosa , Neuromielite Óptica , Substância Branca , Humanos , Substância Branca/diagnóstico por imagem , Feminino , Masculino , Substância Cinzenta/diagnóstico por imagem , Substância Cinzenta/fisiopatologia , Substância Cinzenta/patologia , Adulto , Imageamento por Ressonância Magnética/métodos , Pessoa de Meia-Idade , Neuromielite Óptica/fisiopatologia , Neuromielite Óptica/diagnóstico por imagem , Rede Nervosa/diagnóstico por imagem , Rede Nervosa/fisiopatologia , Disfunção Cognitiva/fisiopatologia , Disfunção Cognitiva/diagnóstico por imagem , Encéfalo/fisiopatologia , Encéfalo/diagnóstico por imagem , Vias Neurais/fisiopatologia , Vias Neurais/diagnóstico por imagemRESUMO
INTRODUCTION: Cognitive impairment has a substantial impact on the daily function of people living with demyelinating diseases. However, the study of cognitive failures and their association with clinical variables in people suffering from neuromyelitis optica spectrum disorder (NMOSD) has been scarce, especially in the latin american (Mexican) population at early and middle stages of the disease. METHOD: We applied the Rao's Brief Repeatable Battery of Neuropsychological tests and obtained data of lesion burden through magnetic resonance imaging (MRI), expression of AQPQ4-IgG antibodies, and degree of disability in 30 patients with NMOSD and 30 healthy participants as a control group. RESULTS: About half of the NMOSD patients (47%) showed some degree of cognitive impairment, especially in the executive domain compared to the control group. Executive function scores were positively associated with the degree of physical disability. We found no associations between cognitive dysfunction and disease duration, AQPQ4-IgG antibodies, lesion burden, nor depression. CONCLUSIONS: Executive functioning impairment is present in NMOSD and may predict the degree of functional disability in patients. Cognitive failures were not associated with immunological or radiological data, which emphasizes the relevance of applying systematic neuropsychological assessments in this clinical population.
Assuntos
Disfunção Cognitiva , Função Executiva , Imageamento por Ressonância Magnética , Neuromielite Óptica , Humanos , Neuromielite Óptica/diagnóstico por imagem , Neuromielite Óptica/fisiopatologia , Feminino , Adulto , México , Disfunção Cognitiva/etiologia , Disfunção Cognitiva/fisiopatologia , Masculino , Pessoa de Meia-Idade , Função Executiva/fisiologia , Testes Neuropsicológicos , Aquaporina 4/imunologiaRESUMO
INTRODUCTION: We aimed to assess the frequency, duration, and severity of area postrema syndrome (APS) during follow-up in neuromyelitis optica spectrum disorder (NMOSD) patients, as well as its association with inflammatory activity and prognostic factors of APS severity in a real-world setting. METHODS: We conducted a retrospective study on a cohort of Latin American (LATAM) NMOSD patients who had experienced APS during their follow-up. Patients from Mexico, Peru, Brazil, Colombia, Panama, Chile and Argentina patients who met 2015 NMOSD criteria were included. We evaluated data on symptom type (nausea, vomiting and/or hiccups), frequency, duration, severity (measured by APS severity scale), association with other NMOSD core relapses, and acute treatments (symptomatic and immunotherapy or plasmapheresis). Logistic regression was conducted to evaluate factors associated with APS severity (vs. mild-moderate). RESULTS: Out of 631 NMOSD patients, 116 (18.3%) developed APS during their follow-up. The most common APS phenotype was severe. Inflammatory activity (i.e., relapses) significantly decreased after the onset of APS. Half of the patients experienced isolated APS with a median duration of 10 days, and the most frequently used acute treatment was IV steroids. All three symptoms were present in 44.6% of the patients. APS symptoms resolved following immunotherapy. Logistic regression did not identify independent factors associated with the severity of APS. CONCLUSIONS: Our findings indicate that 18.3% of NMOSD patients developed APS during the follow-up period, with most patients fulfilling criteria for severe APS. The inflammatory activity decreased after the onset of APS compared to the previous year.
Assuntos
Neuromielite Óptica , Fenótipo , Humanos , Feminino , Masculino , Neuromielite Óptica/terapia , Neuromielite Óptica/epidemiologia , Neuromielite Óptica/fisiopatologia , Adulto , Pessoa de Meia-Idade , Estudos Retrospectivos , Seguimentos , Área Postrema , Índice de Gravidade de DoençaRESUMO
BACKGROUND: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) may be associated with acute symptomatic seizures and chronic epilepsy as well. The clinical features of the seizures and/or accompanying epilepsy seen in each disease group may vary. In this study, we aimed to contribute to the existing literature by describing the clinical features of seizures and epilepsy in our demyelinating patient population. METHODS: We retrospectively analyzed patients who were followed up in our tertiary referral center neurology demyelinating diseases outpatient clinic between 2019 and 2024. Patients who had at least one seizure before, simultaneously, or after the diagnosis of demyelinating disease were included in the study. RESULTS: Among 1735 patients with MS, 40 had experienced at least one epileptic seizure (2.3 %). Thirty patients (1.7 %) had seizures that could not be explained by another factor than MS. When secondary progressive MS (SPMS) and relapsing-remitting MS (RRMS) were compared, the interval between MS-epilepsy diagnosis was longer and seizure recurrence was more in SPMS. However, the prognosis of epilepsy was good in both subtypes. There were 21 patients followed up with antibody-positive neuromyelitis optica spectrum disorder. No patient had a seizure during the follow-up. We identified 56 patients who fulfilled the criteria for MOGAD with high antibody titers. Seizures were observed in three of them (5.4 %). All of them had status epilepticus either at the onset or during the course of the disease. CONCLUSION: Even rare, seizures constitute one of the important clinical features of the inflammatory demyelinating disorders of the central nervous system. The pathophysiologic mechanism underlying seizures in MS is still not clear. Seizures may occur through different mechanisms in patients where seizures are the initial symptom or a sign of relapse and those that occur spontaneously during the progressive course of the disease. Prevalence of status epilepticus was common in MOGAD patients. Given the rarity of the seizures in CNS demyelinating disorders, it is difficult the define clinical and pathophysiological characteristics of accompanying seizures and epilepsy. Future studies conducted on large patient groups will contribute to the existing literature.
Assuntos
Neuromielite Óptica , Convulsões , Humanos , Feminino , Adulto , Masculino , Estudos Retrospectivos , Pessoa de Meia-Idade , Convulsões/etiologia , Neuromielite Óptica/complicações , Neuromielite Óptica/fisiopatologia , Neuromielite Óptica/epidemiologia , Neuromielite Óptica/imunologia , Neuromielite Óptica/diagnóstico , Adulto Jovem , Esclerose Múltipla/complicações , Esclerose Múltipla/epidemiologia , Esclerose Múltipla/diagnóstico , Epilepsia/etiologia , Epilepsia/epidemiologia , Doenças Autoimunes Desmielinizantes do Sistema Nervoso Central/imunologia , Doenças Autoimunes Desmielinizantes do Sistema Nervoso Central/fisiopatologia , Doenças Autoimunes Desmielinizantes do Sistema Nervoso Central/diagnósticoRESUMO
La neuromielitis óptica (NMO) y los trastornos del espectro de neuromielitis óptica (NMOSD) son trastornos poco frecuentes, mediados por anticuerpos del sistema nervioso central (SNC) con predilección por la médula espinal y los nervios ópticos. Existe una fuerte predilección femenina. En el caso de la forma recurrente más común de la enfermedad, que representa del 80% al 90% de los casos, las mujeres están sobrerrepresentadas con una proporción de 5 a 10: 1.6. La edad media de inicio es de 39,7 años. Objetivo: Determinar la causa de neuromielitis óptica en paciente femenina de 24 años de edad. Materiales y métodos: Es una investigación enmarcada en el paradigma positivista, con enfoque cuantitativo. Con un estudio de campo-descriptivo, no experimental, en la modalidad de caso clínico único. El método utilizado fue la historia clínica y consentimiento informado. Resultado: Se presenta el caso de una paciente de sexo femenino de 24 años de edad, sin antecedentes patológicos personales. Presentó pérdida progresiva de la visión de 2 meses de evolución, que se acompañaba de dolor en región cervical de moderada intensidad y en 24 horas presentó parestesia en brazo derecho, afasia, cuadro neurológico que evolucionó hasta presentar cuadriparesia, insuficiencia respiratoria aguda. Conclusión: En IRM de columna cervical se evidencia cambio anormal de la señal medular cervical evidente en secuencias T2 flair lesión hiperintensa longitudinalmente extensa que abarca más de 3 cuerpos vertebrales. Fue tratada con corticoides y plasmaféresis(AU)
Neuromielitis optic (NMO) and neuromielitis optic spectrum disorders (NMOSD) are rare disorders mediated by antibodies of the central nervous system (CNS) with a predilection for the spinal cord and optic nerves. There is a strong female predilection. In the case of the most common recurrent form of the disease, which accounts for 80% to 90% most of the cases are women with a ratio of five to 10: 1.6. The mean age of onset is 39.7 years. Objective: To determine the cause of neuromielitis optica in a 24-year-old female patient. Materials and methods: It is an investigation framed in the positivist paradigm, with a quantitative approach. With a descriptive field study, not experimental, in the single clinical case modality. The method used was the medical history and informed consent. Result: The case of a 24-year-old female patient with no presented personal pathological history. She presented progressive loss of vision of 2 months of evolution, accompanied by pain in the cervical region of moderate intensity and within 24 hours, she presented paresthesia in the right arm, aphasia, a neurological picture that evolved until presenting cuadriparesia, acute respiratory failure. Conclusion: An MRI of the cervical spine shows an abnormal change in the cervical spinal signal evident in T2 sequences flair a longitudinally extensive hiperintensa lesion that encompasses more than 3 vertebral bodies. Her treatment was corticosteroids and plasmapheresis(AU)
Assuntos
Humanos , Feminino , Adulto , Nervo Óptico , Afasia , Sistema Nervoso Central , Neuromielite Óptica/fisiopatologia , Parestesia , Quadriplegia , Insuficiência Respiratória , Medula Espinal , Consentimento Livre e EsclarecidoRESUMO
La neuromielitis óptica (NMO) es un trastorno autoinmune, inflamatorio y desmielinizante del sistema nervioso central con predilección por los nervios ópticos y médula espinal. En el año 2004 se publicó la asociación de NMO con un anticuerpo contra el canal de agua acuaporina 4 (anti-AQP4), como una enfermedad diferente de la esclerosis múltiple (EM). Actualmente se propone el término trastornos del espectro NMO (NMOSD), debido a que las manifestaciones de la enfermedad pueden ser más extensas, afectando además del nervio óptico y médula espinal, al área postrema del bulbo raquídeo, tronco encefálico, diencéfalo y áreas cerebrales típicas (periependimarias, cuerpo calloso, cápsula interna y sustancia blanca subcortical). NMOSD se aplica también a pacientes que cumplen los criterios de NMO y son negativos para anti-AQP4. Dentro de este último grupo se ha detectado en un 20% la presencia de otro anticuerpo, anti-MOG (Glicoproteína oligodendrocítica de mielina) con un mecanismo fisiopatológico diferente pero con una clínica, en algunos casos, similar, y en general con mejor pronóstico. El tratamiento inmunosupresor en la crisis, así como el tratamiento a largo plazo en los casos que esté indicado, es fundamental para evitar secuelas y recidivas. El diagnóstico correcto de esta entidad es fundamental ya que puede ser agravado con el uso de fármacos útiles en el tratamiento de EM. En esta publicación haremos una revisión de la fisiopatología, clínica y criterios diagnósticos de NMOSD, y discutiremos las distintas opciones terapéuticas.
Neuromyelitis optica (NMO) is an autoimmune, inflammatory and de myelinat ing disorder of the central nervous system with a predilection for the optic nerves and spinal cord. In 2004 the association of NMO with an antibody against the water channel aquaporin 4 (anti-AQP4) was published as a different pathology from multiple sclerosis (MS). Currently the term NMO spectrum disorders (NMOSD) is proposed, because the manifestations of the disease can be more extensive, affecting in addition to the optic nerve and spinal cord, the area postrema of the dorsal medulla, brainstem, diencephalon and typical brain areas (periependymal, corpus callosum, internal capsule and subcortical white matter). NMOSD is also applied to patients who meet the NMO criteria and are negative for AQP4-IgG. Within the latter group, the presence of another antibody, anti-MOG, has been detected in 20%, with a different physiopathological mechanism, but with a similar clinic and a better prognosis. The immunosuppressive treatment in the attack, as well as the long-term treatment in the cases that are indicated, is fundamental to avoid sequelaes and recurrences. The correct diagnosis of this entity is essential since it can be aggravated with the use of drugs useful in the treatment of MS. In this publication we will review the pathophysiology, clinical and diagnostic criteria of NMOSD, and discuss the different therapeutic options.
Assuntos
Humanos , Autoanticorpos/imunologia , Neuromielite Óptica/diagnóstico , Neuromielite Óptica/tratamento farmacológico , Autoanticorpos/efeitos adversos , Neuromielite Óptica/fisiopatologia , Neuromielite Óptica/imunologia , Diagnóstico Diferencial , Esclerose Múltipla/diagnósticoRESUMO
Tonic spasms have been most commonly associated with multiple sclerosis. To date, few reports of series of patients with neuromyelitis optica and tonic spasms have been published. Methods: We analyzed the characteristics and frequency of tonic spasms in 19 subjects with neuromyelitis optica. Data was collected using a semi-structured questionnaire for tonic spasms, by both retrospectively reviewing medical records and performing clinical assessment. Results: All patients except one developed this symptom. The main triggering factors were sudden movements and emotional factors. Spasms were commonly associated to sensory disturbances and worsened during the acute phases of the disease. Carbamazepine was most commonly used to treat the symptom and patients showed good response to the drug. Conclusions: Tonic spasms are a common clinical manifestation in patients with neuromyelitis optica. .
Espasmos tônicos têm sido mais frequentemente associados com esclerose múltipla. Foram publicados até agora poucos relatos de série de pacientes com neuromielite óptica e espasmos tônicos. Métodos: Foram analisadas as características e a frequência de espasmos tônicos em 19 indivíduos com neuromielite óptica. Os dados foram coletados por meio de um questionário semiestruturado para espasmos tônicos, mediante a avaliação retrospectiva dos prontuários e a análise dos dados clínicos Resultados: Todos os pacientes com neuromielite óptica exceto um apresentaram espasmos tônicos. Os principais fatores desencadeantes foram movimentos bruscos e fatores emocionais. Espasmos foram frequentemente associados a perturbações sensoriais e se agravaram durante a fase aguda da doença. A carbamazepina foi utilizada frequentemente para tratar os sintomas, com boa resposta. Conclusões: Os espasmos tônicos são manifestações clínicas frequentes em pacientes com neuromielite óptica. .
Assuntos
Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Neuromielite Óptica/complicações , Espasmo/etiologia , Anticonvulsivantes/uso terapêutico , Carbamazepina/uso terapêutico , Neuromielite Óptica/tratamento farmacológico , Neuromielite Óptica/fisiopatologia , Fatores de Risco , Inquéritos e Questionários , Espasmo/tratamento farmacológico , Espasmo/fisiopatologiaRESUMO
Although neuromyelitis optica (NMO) is known to be a more severe disease than relapsing-remitting multiple sclerosis (RRMS), few studies comparing both conditions in a single center have been done. Methods: Comparison of our previously published cohort of 41 NMO patients with 177 RRMS patients followed in the same center, from 1994 to 2007. Results: Mean age of onset was 32.6 for NMO and 30.2 for RRMS (p=0.2062) with mean disease duration of 7.4 years for NMO and 10.3 years for RRMS. Patients with NMO had a higher annualized relapse rate (1.0 versus 0.8, p=0.0013) and progression index (0.9 versus 0.6, p≪0.0001), with more patients reaching expanded disability status scale (EDSS) 6.0 (39 versus 17%, p=0.0036). The odds ratio for reaching EDSS 6.0 and being deceased due to NMO in comparison to RRMS were, respectively, 3.14 and 12.15. Conclusion: Patients with NMO have a more severe disease than patients with RRMS, including higher risk of dying of a demyelinating disease. .
Embora a neuromielite óptica (NMO) seja reconhecida como mais grave que a esclerose múltipla remitente recorrente (EMRR), existem poucos estudos comparando as duas doenças em um único centro. Métodos: Comparação de nossa coorte publicada de 41 pacientes com NMO com 177 pacientes com EMRR seguidos no mesmo centro, de 1994 a 2007. Resultados: A média de idade inicial foi de 32,6 anos em NMO e 30,2 anos em EMRR (p=0,2062), com tempo médio de doença de 7,4 anos para NMO e 10,3 anos EMRR. Pacientes com NMO apresentaram maior taxa anualizada de surtos (1,0 versus 0,8, p=0,0013) e índice de progressão (0,9 versus 0,6, p≪0,0001), com mais pacientes atingindo EDSS 6,0 (39 versus 17%, p=0,0036). Os riscos relativos de se alcançar 6,0 EDSS e falecer em decorrência de NMO em comparação com EMRR, foram, respectivamente, 3,14 e 12,15. Conclusão: Pacientes com NMO têm uma doença mais grave do que os pacientes com EMRR, incluindo maior risco de morrer de uma doença desmielinizante. .
Assuntos
Adulto , Feminino , Humanos , Masculino , Adulto Jovem , Esclerose Múltipla Recidivante-Remitente , Neuromielite Óptica , Idade de Início , Progressão da Doença , Métodos Epidemiológicos , Esclerose Múltipla Recidivante-Remitente/mortalidade , Esclerose Múltipla Recidivante-Remitente/patologia , Esclerose Múltipla Recidivante-Remitente/fisiopatologia , Neuromielite Óptica/mortalidade , Neuromielite Óptica/patologia , Neuromielite Óptica/fisiopatologia , Recidiva , Fatores de Risco , Índice de Gravidade de Doença , Fatores de TempoRESUMO
Neuromyelitis optica (NMO) is an inflammatory disease of central nervous system classically characterized by acute, severe episodes of optic neuritis and longitudinally extensive transverse myelitis, usually with a relapsing course. The identification of an autoantibody exclusively detected in NMO patients against aquaporin-4 (AQP-4) has allowed identification of cases beyond the classical phenotype. Brain lesions, once thought as infrequent, can be observed in NMO patients, but lesions have different characteristics from the ones seen in multiple sclerosis. Additionally, some AQP-4 antibody positive patients may present with a variety of symptoms not being restricted to optic neuritis and acute myelitis during the first attack or in a relapse. Examples are not limited to, but may include patients only with brain and/or brainstem lesions, narcolepsy with hypothalamic lesions or patients with intractable hiccups, nausea and vomiting. The prompt identification of NMO patients with atypical presentations may benefit these patients with institution of early treatment to reduce disability and prevent further attacks.
Neuromielite óptica (NMO) é uma doença inflamatória do sistema nervoso central caracterizada classicamente por neurite óptica grave e mielite transversa longitudinalmente extensa, com um curso usualmente recorrente. A identificação do anticorpo detectado exclusivamente nos pacientes com NMO contra a aquaporina-4 (AQP-4) permitiu a identificação de casos além do fenótipo clássico. Lesões cerebrais, que antes eram descritas como infrequentes, podem ser observadas em pacientes com NMO, mas as lesões possuem características diferentes das lesões observadas na esclerose múltipla. Além disso, alguns pacientes positivos para o anticorpo contra a AQP-4 podem apresentar uma variedade de sintomas não restritos à neurite óptica e mielite aguda, seja durante o primeiro ataque seja em uma recorrência. Exemplos não estão limitados aos descritos a seguir, mas incluem pacientes com lesões cerebrais e/ou tronco cerebral, narcolepsia com lesões hipotalâmicas ou pacientes com quadros intratáveis de soluços, náusea e vômitos. A identificação rápida dos pacientes com NMO com apresentações atípicas pode beneficiar estes pacientes com a instituição precoce do tratamento a fim de reduzir a incapacidade e prevenir ataques subsequentes.
Assuntos
Adulto , Humanos , /imunologia , Neuromielite Óptica/diagnóstico , Autoanticorpos/sangue , Biomarcadores/sangue , Imageamento por Ressonância Magnética , Neuromielite Óptica/fisiopatologiaAssuntos
Humanos , Masculino , Feminino , Espectroscopia de Ressonância Magnética , Doenças Desmielinizantes Hereditárias do Sistema Nervoso Central , Mielite/epidemiologia , Mielite/patologia , Neuromielite Óptica/diagnóstico , Neuromielite Óptica/fisiopatologia , Neuromielite Óptica/imunologia , Medula Espinal/fisiopatologia , Nervo Óptico/fisiopatologiaRESUMO
Optic neuromyelitis is characterized by simultaneous or successive necrotizing lesions involving the optic nerves and the spinal cord. We report two females with the disease, aged 30 and 34 years old. In the latter, a neuropathological study was done. Both patients had clinical, neuroradiological and pathological features that differed from those of primary demyelinating syndromes such as multiple sclerosis. These patients illustrate the selectivity of optic nerve and spinal cord lesions. The latter involve mainly pyramidal and Goll tracts while, within the necrotizing lesions of the optic chiasma, the fibers of the unaffected optic nerve are spared. This pattern suggests a selective injury to some population of axons. Blood vessels were not affected in the necrotizing areas and the lesions did not follow a vascular territory, therefore a vascular mechanism causing the disease is unlikely. The clinical and neuropathological features of neuromyelitis optic suggest a selective involvement of some axons
Assuntos
Humanos , Feminino , Adulto , Neuromielite Óptica/fisiopatologia , Necrose , Epêndima/patologia , Nervo Óptico/patologiaRESUMO
Se presentan los hallazgos clínico-pathológicos de diez casos de enfermedad de Devic. La enfermedad fue más frecuente en mujeres adultas y el tiempo de evolución promedio en esta serie fue de diez meses. Las manifestaciones por lesión de la médula espinal fueron las más sobresalientes y casi todos los enfermos murieron por complicaciones pulmonares. Los hallazgos neuropatológicos más importantes fueron desmielinización, infiltrado linfocitario perivascular y cavitación del quiasma óptico y de la médula espinal. Algunos autores consideran la enfermedad de Devic como una forma de esclerosis múltiple y otros como entidad aparte, pero se sabe que es una enfermedad desmielinizante primaria confinada a nervios, quiasma y bandeletas ópticos y a la médula espina, en que el grado de destrucción es mayor aún que en las placas más antiguas de la esclerosis múltiple
Assuntos
Humanos , Adulto , Pessoa de Meia-Idade , Nervo Óptico/patologia , Neuromielite Óptica/fisiopatologia , Neuromielite Óptica/patologia , Quiasma Óptico , Medula Espinal/patologia , Medula Espinal/fisiopatologiaRESUMO
Con el fin de conocer el comportamiento de la neuromielitis óptica (NMO) o síndrome de Devic, se revisaron las historias de los pacientes hospitalizados entre 1980 y 1994 en el Servicio de Neurología del Hospital Universitario San Vicente de Paúl de Medellín. Del total de 2576 historias revisadas, se encontraron 21 casos con este síndrome, lo que equivale a 0.8 por ciento de la patología admitida en el servicio. De los 21 pacientes, cuatro presentaron el compromiso clásico de neuritis óptica y mielitis, en los otros 17 se encontraron alteraciones del SNC a otros niveles (cerebelo, tallo cerebral, hemisferios cerebrales y otros nervios craneanos). La frecuencia fue mayor en el sexo femenino. La edad de presentación más frecuente fue entre 10 y 20 años (33.3 por ciento) y le siguió entre 41 y 50 años (23 por ciento). El compromiso visual precedió al medular en 61 por ciento. Se trataron 19 pacientes (90 por ciento) con prednisona y a cuatro (19 por ciento) se les adicionó ciclofosfamida. El compromiso medular mejoró en 80 por ciento de los casos y el defecto visual en 75 por ciento. Proponemos se estudie este síndrome en los diferentes centros de neurología del país para establecer su comportamiento entre nosostros.